Synektik aiming for 30-40% growth by 2021 

IT company Synektik has revealed its strategy for 2017-2021, which targets an average annual revenue growth of 30-40 percent and a three-fourfold increase in the EBITDA margin at the end of the financial year 2020/2021 compared to the average of 8 percent in 2014-2016, the company said. Synektik’s development plans are based on a focus on oncology, cardiology and neurology, as well as maintaining a strong position in the market of solutions for radiology. At the same time, the Group wants to grow and develop new solutions in its "Evolution" platform. "We will reach entirely new audiences – specialists in the fields of oncology, cardiology and neurology at medical centers. Considering their needs we formulated a new company offer. We will also systematically expand the offer of products for therapy – the area of ​​health, in which there are the biggest expenses," said the company's president Cezary Kozanecki. Synektik Group is a provider of products, services and IT solutions for diagnostic imaging and medicine. The company is also Poland's first commercial producer of radiopharmaceuticals used in the diagnosis of cancer (PET). Synektik was founded in 2001 and since August 2011, the company's shares have been listed on the NewConnect market. In October 2014 it debuted on the WSE regulated market.